-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Comparing SomaLogic (NASDAQ:SLGC) & OmniAb (NASDAQ:OABI)
Comparing SomaLogic (NASDAQ:SLGC) & OmniAb (NASDAQ:OABI)
SomaLogic (NASDAQ:SLGC – Get Rating) and OmniAb (NASDAQ:OABI – Get Rating) are both small-cap business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.
Analyst Recommendations
This is a summary of recent ratings and price targets for SomaLogic and OmniAb, as provided by MarketBeat.
Get SomaLogic alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
SomaLogic | 0 | 0 | 3 | 0 | 3.00 |
OmniAb | 0 | 0 | 4 | 0 | 3.00 |
SomaLogic currently has a consensus price target of $11.00, indicating a potential upside of 340.00%. OmniAb has a consensus price target of $10.25, indicating a potential upside of 164.18%. Given SomaLogic's higher possible upside, equities research analysts plainly believe SomaLogic is more favorable than OmniAb.
Insider and Institutional Ownership
66.8% of SomaLogic shares are held by institutional investors. Comparatively, 42.3% of OmniAb shares are held by institutional investors. 12.9% of SomaLogic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.Earnings & Valuation
This table compares SomaLogic and OmniAb's gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
SomaLogic | $81.63 million | 5.62 | -$87.55 million | ($0.46) | -5.43 |
OmniAb | N/A | N/A | -$520,000.00 | N/A | N/A |
OmniAb has lower revenue, but higher earnings than SomaLogic.
Risk & Volatility
SomaLogic has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, OmniAb has a beta of -1.18, indicating that its share price is 218% less volatile than the S&P 500.
Profitability
This table compares SomaLogic and OmniAb's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
SomaLogic | -81.72% | -18.23% | -15.92% |
OmniAb | N/A | N/A | -3.50% |
About SomaLogic
(Get Rating)
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.
About OmniAb
(Get Rating)
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.
SomaLogic (NASDAQ:SLGC – Get Rating) and OmniAb (NASDAQ:OABI – Get Rating) are both small-cap business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.
SomaLogic(納斯達克:SLGC-GET評級)和OmniAb(納斯達克:OABI-GET評級)都是小盤股,但哪隻是優秀股?我們將根據這兩家公司的股息、風險、分析師建議、盈利能力、機構所有權、收益和估值來比較它們的實力。
Analyst Recommendations
分析師建議
This is a summary of recent ratings and price targets for SomaLogic and OmniAb, as provided by MarketBeat.
這是由MarketBeat提供的SomaLogic和OmniAb最近的評級和目標價摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
SomaLogic | 0 | 0 | 3 | 0 | 3.00 |
OmniAb | 0 | 0 | 4 | 0 | 3.00 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
SomaLogic | 0 | 0 | 3 | 0 | 3.00 |
OmniAb | 0 | 0 | 4 | 0 | 3.00 |
SomaLogic currently has a consensus price target of $11.00, indicating a potential upside of 340.00%. OmniAb has a consensus price target of $10.25, indicating a potential upside of 164.18%. Given SomaLogic's higher possible upside, equities research analysts plainly believe SomaLogic is more favorable than OmniAb.
SomaLogic目前的普遍目標價為11美元,表明潛在上行空間為340.00%。OmniAb的一致目標價為10.25美元,表明潛在上漲164.18%。考慮到SomaLogic更有可能的上行空間,股票研究分析師顯然認為SomaLogic比OmniAb.
Insider and Institutional Ownership
內部人與機構持股
Earnings & Valuation
收益與估值
This table compares SomaLogic and OmniAb's gross revenue, earnings per share and valuation.
該表格比較了SomaLogic和OmniAb的毛收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
SomaLogic | $81.63 million | 5.62 | -$87.55 million | ($0.46) | -5.43 |
OmniAb | N/A | N/A | -$520,000.00 | N/A | N/A |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
SomaLogic | 8163萬美元 | 5.62 | -8,755萬元 | ($0.46) | -5.43 |
OmniAb | 不適用 | 不適用 | -$520,000.00 | 不適用 | 不適用 |
OmniAb has lower revenue, but higher earnings than SomaLogic.
OmniAb的收入低於SomaLogic,但收益高於SomaLogic。
Risk & Volatility
風險與波動性
SomaLogic has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, OmniAb has a beta of -1.18, indicating that its share price is 218% less volatile than the S&P 500.
SomaLogic的貝塔係數為1.53,表明其股價的波動性比標準普爾500指數高53%。相比之下,OmniAb的貝塔係數為-1.18,這表明其股價的波動性比標準普爾500指數低218%。
Profitability
盈利能力
This table compares SomaLogic and OmniAb's net margins, return on equity and return on assets.
此表比較了SomaLogic和OmniAB的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
SomaLogic | -81.72% | -18.23% | -15.92% |
OmniAb | N/A | N/A | -3.50% |
淨利潤率 | 股本回報率 | 資產回報率 | |
SomaLogic | -81.72% | -18.23% | -15.92% |
OmniAb | 不適用 | 不適用 | -3.50% |
About SomaLogic
關於SomaLogic
(Get Rating)
(獲取評級)
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.
SomaLogic公司是美國的一家蛋白質生物標記物發現和臨牀診斷公司。它開發慢速修飾適體(SOMAmers),這是一種針對其同源蛋白質的改良核酸蛋白質結合試劑;並提供專有的SomaScan服務,提供複雜生物樣本中的多重蛋白質檢測和蛋白質水平的量化。該公司的SOMAmers/SomaScan技術使研究人員能夠分析各種類型的生物樣本以尋找蛋白質生物標記物簽名,這可用於藥物發現和開發。其SomaScan的生物標誌物發現有助於在各種疾病領域的診斷應用,包括心血管和代謝性疾病、非酒精性脂肪性肝炎、健康等。該公司還提供SomaSignal僅用於研究和實驗室開發的測試。它以製藥和生物技術公司以及學術研究機構為重點,為研究和臨牀客户提供服務,並通過評估蛋白質-蛋白質和蛋白質-基因網絡,促進藥物開發、臨牀試驗分析和新的人類生物學見解。該公司成立於1999年,總部設在科羅拉多州博爾德市。
About OmniAb
關於OmniAb.
(Get Rating)
(獲取評級)
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
OmniAbInc.是一家生物技術公司,在美國提供治療性抗體發現技術。該公司的發現平臺為行業合作伙伴提供了訪問各種抗體譜系和篩選技術的機會,以實現下一代療法的發現。它的OmniAbPlatform是專有轉基因動物的生物智能,包括Omni大鼠、OmniChicken和OmniMouse,這些動物已經經過基因改造,產生具有人類序列的抗體,以促進人類候選治療的開發。該公司的OmniFlic(轉基因大鼠)和OmniClic(轉基因雞)通過共同的輕鏈方法和OmniTaur滿足了行業對雙特異性抗體應用的需求,OmniTaur具有針對複雜靶標的奶牛抗體的獨特結構屬性。該公司成立於2012年,總部位於加利福尼亞州埃默裏維爾。
Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.
接受SomaLogic日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對SomaLogic和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧